Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies 2019


Highly Sensitive Direct Quantification of cfmiRNAs for Biomarker Profiling by Next Generation Sequencing (NGS)

Sergio Barberan Soler, Director of Sequencing Technologies, Somagenics, Inc

Cell-free miRNAs (cf-miRNAs) are promising diagnostic and prognostic biomarkers for cancer and other diseases. cf-miRNAs are highly stable in biofluids and more attractive for NGS- based detection compared to, other more labile biomolecules. However, NGS miRNA detection from biofluids is limited by highly biased, error prone library preparation technologies. RealSeq® addresses these issues with proven best in class accuracy of detection [1]. This novel platform includes a kit designed to profile miRNAs from biofluids (RealSeq®-Biofluids) with a four-fold increase in number of miRNAs detected over commercially available technologies. Additionally, we have developed RealSeq®-T, the first and only targeted sequencing approach to detect panels of cf-miRNAs (up to 1,200) directly from plasma (no RNA extraction) demonstrating nearly 95% of sequenced reads mapped to the miRNA panel. The RealSeq® technology platform facilitates the use of cf-miRNAs as clinical biomarkers for liquid biopsy applications.

Add to Calendar ▼2019-03-27 00:00:002019-03-29 00:00:00Europe/LondonLiquid Biopsies 2019Liquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island,